Biopharmaceutical research companies are conducting or have conducted more than 3,200 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals (1999 to present).
Of the more than 3,200 clinical trials, 1,754 target the nation’s six most debilitating chronic diseases —asthma, cancer, diabetes, heart disease, mental illnesses and stroke.
“The 3,266 clinical studies of new medicines conducted in Indiana since 1999 by biopharmaceutical research companies have significantly benefited patients, the state’s economy and the advancement of science and patient care. These companies hire the state’s university medical schools and science centers, hospitals and contract research organizations to conduct the studies, which account for 45 to 75 percent of the average $1.2 billion cost of developing a medicine." --Andrew Dahlem, Ph.D, VP, COO, Lilly Research Laboratories